Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
Front Oncol
.
2020 Sep 10:10:1726.
doi: 10.3389/fonc.2020.01726.
eCollection 2020.
Authors
Rafael Rosell
1
,
Martyna Filipska
1
,
Imane Chaib
1
,
David Lligé
1
,
Fernando Laguia
1
Affiliation
1
Germans Trias i Pujol Research Institute and Hospital, Badalona, Spain.
PMID:
33014853
PMCID:
PMC7511626
DOI:
10.3389/fonc.2020.01726
No abstract available
Keywords:
Akt; CRISPR; MAPK; NSCLC; PD-1; PD-L1; PI3K; T Cells.
Publication types
Comment